Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Recruiting now · Phase 1/Phase 2
Conditions studied: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
In brief
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Key facts
- Study ID
- NCT05431270
- Run by
- Phanes Therapeutics
- People needed
- 40
- Starts
- 2022-08-11
- Expected to finish
- 2028-08-01
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Carolina BioOncology Institute — Huntersville, North Carolina, United States (enrolling)
- Sarah Cannon Research Institute University of Oklahoma — Oklahoma City, Oklahoma, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- NEXT Oncology — Fairfax, Virginia, United States (enrolling)
- Tranquility Research — Webster, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.